Mode
Text Size
Log in / Sign up

FH-deficient uterine leiomyoma in young women requires IHC screening and lifelong renal surveillanceRare Genetic Marker Linked to Multiple Uterine Fibroids

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider IHC screening and lifelong renal surveillance for young women with large, multiple, or recurrent leiomyomas.

This case report and literature review describes a 35-year-old woman presenting with multiple uterine leiomyomas. The authors synthesize clinical evidence regarding fumarate hydratase (FH) deficiency in uterine tumors, highlighting the importance of immunohistochemistry (IHC) for identifying FH loss and 2SC positivity. Initial histopathology showed CD10 negativity and SMA/desmin/h-caldesmon/ER positivity, while subsequent IHC confirmed FH deficiency.

The report emphasizes that clinical suspicion should be high in young women presenting with large, multiple, recurrent, or hypervascular leiomyomas, especially when familial clustering is present. While abdominal CT imaging in this specific case showed no renal abnormalities, the authors note that patients with confirmed FH-deficient tumors require lifelong surveillance for renal and dermatologic involvement.

A primary limitation of this evidence is the small sample size of a single case report, which means the findings are not generalizable to the broader population of uterine leiomyoma patients. However, it underscores the necessity of IHC screening and genetic counseling in specific clinical contexts. Clinicians should consider these factors when managing young women with complex uterine fibroid presentations.

Doctors reported on a 35-year-old woman who had several large, recurring uterine fibroids. While many women develop these noncancerous growths, this specific case showed a rare genetic marker called fumarate hydratase (FH) deficiency. This finding is important because it can be linked to a condition that affects other organs.

The patient underwent surgery and later testing confirmed the presence of the FH deficiency. Although her kidney scans were normal at the time of the report, the discovery means she may need regular checkups for her kidneys and skin. Because this was a single case study, it is not a common finding for all women with fibroids.

Doctors suggest that young women with many large or recurring fibroids should be screened for these specific markers. If found, patients can receive specialized genetic counseling. This helps doctors monitor the patient more closely over time to manage potential risks early.

What this means for you:
Rare genetic markers in some uterine fibroid cases may require long-term monitoring of other organs like kidneys.

Common questions

What is the significance of finding a genetic marker like FH deficiency?

Finding an FH deficiency in someone with many uterine fibroids can indicate a specific syndrome. This means the patient might need lifelong monitoring of her kidneys and skin. While this was only one case, it helps doctors identify patients who need more frequent checkups to stay healthy.

Who is most likely to be tested for these specific markers?

Doctors may look for these markers in younger women who have many large, recurring, or very blood-rich fibroids. They also consider cases where there is a pattern of similar issues in the family. These patients can then receive specialized genetic counseling and regular screenings.

Does this mean all uterine fibroids are linked to genetics?

No, most uterine fibroids are not linked to this specific condition. This was a single case report of one patient. Because the sample size is very small, these results cannot be applied to every woman who has fibroids. You should talk to your doctor about your specific symptoms.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedJun 2026
View Original Abstract ↓
BackgroundUterine leiomyoma is the most common benign tumor in the female reproductive system. Fumarate hydratase (FH)-deficient leiomyoma is a rare subtype characterized by distinctive histopathological and immunophenotypic features and may be associated with hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome.Case descriptionA 35-year-old Han Chinese woman, gravida 1 para 1, was admitted in 2021 because of multiple uterine leiomyomas. Pelvic ultrasound demonstrated an enlarged uterus with multiple intramural masses, including a cervical lesion measuring 12.8×10.8×10.3 cm. The patient underwent open abdominal myomectomy. Histopathology showed multiple leiomyomas with focally increased cellularity and occasional mitotic activity. Immunohistochemistry demonstrated CD10 negativity and positivity for SMA, desmin, h-caldesmon, and ER, whereas FH and 2SC staining were not performed at that time. Five months after surgery, multiple intramural masses were detected on ultrasound, but the patient was lost to follow-up for approximately 4 years. In 2025, she presented with irregular vaginal bleeding. Imaging revealed multiple large hypervascular uterine masses with ill-defined margins, heterogeneous echogenicity, and degenerative changes on MRI. The patient reported that both her mother and sister had undergone hysterectomy for uterine fibroids. She subsequently underwent total hysterectomy with bilateral salpingo-oophorectomy. Pathological examination demonstrated multiple intramural leiomyomas with degeneration and focal infarction. Immunohistochemistry revealed loss of FH expression and diffuse strong 2SC positivity,confirming FH-deficient uterine leiomyoma. Abdominal CT showed no renal abnormality. FH genetic testing, genetic counseling, and lifelong renal and dermatologic surveillance were recommended, but the patient declined genetic testing. At 6-month follow-up, she remained asymptomatic without imaging evidence of recurrence.ConclusionFH-deficient uterine leiomyoma should be suspected in young women presenting with large, multiple, recurrent, hypervascular leiomyomas and familial clustering of uterine fibroids. Early FH/2SC immunohistochemical screening, genetic counseling, and long-term renal surveillance are important for identifying suspected HLRCC risk and guiding individualized management. Even when germline FH testing is declined, patients with FH-deficient uterine leiomyoma should not be managed as routine leiomyoma cases, but should receive counseling regarding suspected HLRCC risk, dermatologic assessment, and lifelong renal surveillance.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.